Rat study suggests Allergan's failed antidepressant rapastinel may work as opioid addiction treatment
Last month, when Allergan’s $AGN once-touted pipeline star rapastinel crashed and burned a slate of pivotal depression studies, it looked like the experimental modulator …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
